Protea Biosciences Group (PRGBQ) stock price, revenue, and financials

Protea Biosciences Group market cap is $794 , and annual revenue was $2.45 m in FY 2016

$794

PRGBQ Mkt cap, 27-Apr-2020

$328.1 K

Protea Biosciences Group Revenue Q2, 2017
Protea Biosciences Group Gross profit (Q2, 2017)-61.4 K
Protea Biosciences Group Gross profit margin (Q2, 2017), %(18.7%)
Protea Biosciences Group Net income (Q2, 2017)-5.5 M
Protea Biosciences Group EBIT (Q2, 2017)-1.4 M
Protea Biosciences Group Cash, 30-Jun-201782.7 K
Protea Biosciences Group EV12.2 M

Protea Biosciences Group Income Statement

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016

Revenue

713.0k834.3k1.2m1.8m2.0m2.4m

Revenue growth, %

45%13%22%

Cost of goods sold

871.9k721.7k1.7m

Gross profit

896.4k1.3m741.0k

Gross profit Margin, %

51%64%30%

R&D expense

6.2m4.6m

General and administrative expense

5.2m5.2m

Operating expense total

11.5m9.8m11.6m8.4m6.2m

EBIT

(10.8m)(9.0m)(10.3m)(10.7m)(7.1m)(5.5m)

EBIT margin, %

(1511%)(1076%)(844%)(605%)(356%)(225%)

Interest expense

729.6k541.8k1.1m781.6k2.4m10.2m

Investment income

910.0k1.5m

Pre tax profit

(11.5m)(9.5m)(11.4m)(11.5m)(9.6m)(15.6m)

Net Income

(11.5m)(9.5m)(11.4m)(11.5m)(9.6m)(15.6m)

Protea Biosciences Group Balance Sheet

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016

Cash

505.3k27.6k1.1m322.9k6.5k78.7k

Accounts Receivable

76.7k127.7k216.9k273.9k195.8k1.3m

Prepaid Expenses

141.4k29.6k304.7k54.0k98.2k

Inventories

223.3k905.2k465.3k161.3k111.1k92.2k

Current Assets

1.4m1.4m2.5m931.3k411.6k728.9k

PP&E

3.3m2.8m2.9m3.0m2.6m2.5m

Total Assets

4.8m4.2m5.4m4.0m3.0m3.2m

Accounts Payable

310.9k764.5k1.1m1.3m33.0k1.8m

Short-term debt

398.4k1.4m3.8m4.5m4.3m

Current Liabilities

7.1m10.0m6.2m7.8m9.6m15.6m

Long-term debt

2.2m2.1m1.6m4.8m4.7m

Non-Current Liabilities

2.2m

Total Debt

2.6m3.5m5.4m9.3m9.0m

Common Stock

2.7k3.2k6.5k6.7k13.3k16.2k

Preferred Stock

334.0

Additional Paid-in Capital

32.9m39.1m55.4m64.3m71.3m81.1m

Retained Earnings

(79.6m)(95.2m)

Total Equity

(4.5m)(7.9m)(3.0m)(5.6m)(8.3m)(14.1m)

Debt to Equity Ratio

-0.6 x-0.4 x-1.8 x-1.7 x-1.1 x

Debt to Assets Ratio

0.5 x0.8 x1 x2.3 x3 x

Financial Leverage

-1.1 x-0.5 x-1.8 x-0.7 x-0.4 x-0.2 x

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Cash

15.4k657.0k201.2k467.1k56.3k89.1k308.6k41.0k313.3k277.5k118.3k80.3k121.4k33.8k174.0k15.5k82.7k

Accounts Receivable

92.2k89.7k126.3k61.3k403.9k228.4k66.6k115.3k83.3k264.5k250.7k297.9k108.8k318.5k375.1k340.0k88.8k202.5k

Prepaid Expenses

105.8k134.6k74.2k122.6k50.0k57.3k103.9k134.6k78.6k69.0k55.0k205.7k66.9k43.1k122.0k70.7k150.7k177.0k

Inventories

262.9k350.9k767.9k830.3k600.7k607.6k591.4k553.4k505.5k262.2k129.2k56.5k65.6k102.8k146.9k145.6k40.6k38.3k

Current Assets

2.1m1.3m1.6m1.1m1.5m1.2m830.6k1.6m1.4m747.6k515.3k681.5k275.2k464.4k818.1k556.3k295.7k500.4k

PP&E

3.1m3.2m3.3m3.0m2.6m2.6m2.4m3.3m3.2m3.1m2.8m3.0m2.9m2.4m2.8m2.8m2.3m2.3m

Total Assets

5.2m4.5m4.9m4.1m4.1m3.8m3.2m4.9m4.6m3.9m3.6m3.8m3.2m2.9m3.7m3.3m2.7m2.8m

Accounts Payable

437.8k725.1k590.6k492.9k1.2m1.1m410.7k862.5k2.6m2.6m1.5m1.3m30.5k1.3m1.3m1.9m1.7m1.1m

Short-term debt

425.4k439.5k(898.9k)(1.3m)1.5m1.3m5.8m4.2m4.5m4.8m4.3m5.7m6.2m4.8m3.4m7.1m6.8m7.5m

Current Liabilities

5.2m7.5m9.1m9.5m10.4m10.3m8.8m7.9m10.2m14.6m8.8m9.7m10.8m10.5m9.6m17.4m17.2m12.9m

Long-term debt

2.3m2.3m2.6m2.2m1.9m1.8m1.7m4.8m4.7m4.6m5.0m5.1m5.0m4.6m4.9m4.8m4.8m4.8m

Non-Current Liabilities

2.3m2.3m

Total Debt

2.7m2.8m1.7m968.1k3.4m3.1m7.5m9.0m9.1m9.3m9.3m10.8m11.2m9.4m8.4m11.9m11.6m12.3m

Total Liabilities

14.5m19.2m

Common Stock

386.02.7k2.8k2.9k3.0k3.7k4.2k5.0k6.5k6.6k6.6k9.9k11.5k11.9k13.4k13.4k13.4k21.0k39.5k

Additional Paid-in Capital

53.2k32.3m35.1m36.2m37.7m41.3m44.0m47.6m55.5m56.1m56.3m65.7m67.3m68.1m71.5m71.6m72.1m84.7m94.8m

Retained Earnings

43.0m(75.3m)(77.6m)(80.7m)(82.5m)(88.0m)(101.1m)(106.6m)

Total Equity

(127.1k)(2.2m)(5.3m)(6.8m)(7.5m)(8.3m)(8.3m)(7.3m)(5.6m)(8.5m)(12.9m)(7.3m)(8.0m)(9.5m)(9.2m)(10.9m)(15.9m)(16.4m)(11.8m)

Debt to Equity Ratio

-1.2 x-0.5 x-0.3 x-0.1 x-0.4 x-0.4 x-1 x-1.6 x-1.1 x-0.7 x-1.3 x-1.4 x-1.2 x-1 x-0.8 x-0.7 x-0.7 x-1 x

Debt to Assets Ratio

0.5 x0.6 x0.4 x0.2 x0.8 x0.8 x2.3 x1.8 x2 x2.4 x2.6 x2.8 x3.5 x3.2 x2.3 x3.6 x4.4 x4.3 x

Financial Leverage

-2.4 x-0.9 x-0.7 x-0.5 x-0.5 x-0.5 x-0.4 x-0.9 x-0.5 x-0.3 x-0.5 x-0.5 x-0.3 x-0.3 x-0.3 x-0.2 x-0.2 x-0.2 x

Protea Biosciences Group Cash Flow

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(11.5m)(9.5m)(11.4m)(11.5m)(9.6m)(15.6m)

Depreciation and Amortization

1.3m1.0m844.9k825.8k686.8k678.5k

Accounts Receivable

(26.0k)(81.1k)(93.1k)(60.0k)78.1k(260.1k)

Inventories

43.7k(681.8k)439.9k304.0k146.6k41.7k

Accounts Payable

780.8k(233.4k)(2.0m)810.6k148.6k458.0k

Cash From Operating Activities

(8.0m)(8.5m)(10.2m)(7.3m)(5.6m)(4.2m)

Cash From Investing Activities

(1.2m)(358.2k)(477.9k)115.6k1.0m1.5m

Long-term Borrowings

(402.0k)(278.0k)(1.2m)(1.7m)(617.7k)(1.3m)

Cash From Financing Activities

9.3m8.4m11.7m6.5m4.2m2.8m

Net Change in Cash

94.6k(477.7k)1.1m(763.5k)(316.4k)72.3k

Interest Paid

338.8k372.8k383.3k319.9k352.1k317.6k

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Net Income

(13.0k)(8.5m)(2.9m)(5.5m)(7.8m)(2.6m)(5.4m)(7.9m)(2.7m)(6.2m)(10.8m)(3.0m)(5.3m)(7.6m)(1.1m)(2.9m)(8.4m)(5.9m)(11.4m)

Depreciation and Amortization

943.6k231.5k488.7k749.2k204.8k412.2k633.5k206.0k430.8k627.1k174.7k356.1k532.6k159.0k319.1k496.5k157.3k306.4k

Accounts Receivable

(41.5k)(13.0k)(49.7k)15.3k(276.2k)(100.7k)56.1k99.5k132.4k(50.9k)23.2k(24.0k)165.1k(122.6k)(179.3k)(144.1k)348.1k234.4k

Inventories

4.2k(127.6k)(544.5k)(607.0k)304.5k297.6k313.8k(88.0k)(40.2k)203.1k77.4k149.4k159.1k44.6k521.01.9k(1.4k)900.0

Accounts Payable

(521.7k)(139.4k)552.3k108.7k(1.0m)(1.2m)(813.7k)657.4k1.6m1.8m241.0k35.8k175.5k(59.9k)(39.2k)552.9k(84.1k)(349.1k)

Cash From Operating Activities

(13.0k)(7.2m)(2.5m)(4.2m)(6.7m)(2.3m)(4.6m)(7.3m)(1.4m)(3.3m)(4.5m)(1.4m)(3.3m)(4.4m)(1.3m)(2.8m)(3.4m)(834.5k)(2.3m)

Cash From Investing Activities

(636.7k)(162.1k)(341.7k)(340.6k)(9.5k)(196.1k)(42.7k)(51.9k)486.0k214.3k(7.4k)90.0k79.3k637.1k1.4m1.5m(19.9k)15.5k

Long-term Borrowings

(295.2k)(72.0k)(257.9k)(255.3k)(24.8k)(359.5k)(706.2k)(169.1k)(564.6k)(746.5k)(63.7k)(311.2k)(466.9k)(7.8k)(201.1k)(973.9k)(309.6k)(708.3k)

Cash From Financing Activities

25.0k8.1m2.4m4.5m6.6m2.3m5.1m7.3m698.4k2.0m3.3m1.2m3.0m4.0m652.9k1.7m1.9m791.1k2.3m

Net Change in Cash

12.0k246.3k(304.1k)(38.1k)(448.9k)61.5k281.0k13.4k(773.0k)(808.9k)(968.1k)(242.5k)(201.5k)(289.0k)(6.4k)167.6k(6.4k)(63.2k)3.9k

Interest Paid

267.6k43.3k184.2k315.2k45.7k225.0k403.1k64.6k136.1k193.9k41.3k124.3k207.1k47.5k122.4k

Protea Biosciences Group Ratios

USDQ2, 2011

Protea Biosciences Group Employee Rating

3.15 votes
Culture & Values
3.3
Work/Life Balance
3.3
Senior Management
3.5
Salary & Benefits
4.1
Career Opportunities
2.2
Source